US HPV vaccine uptake low compared to other adolescent immunizations

13 February 2018

While human papilloma virus (HPV) vaccination rates have risen substantially, just 29% of adolescents received a first dose of the vaccine by their 13th birthday, according to a new seven-year study of medical claims by the Blue Cross Blue Shield Association (BCBSA) Health of America Report.

First-dose HPV vaccination rates grew 55% among Blue Cross and Blue Shield (BCBS) commercially insured adolescent members from 2010 through 2016. Despite the growth, HPV vaccination lags behind meningococcal and Tdap vaccines, which have rates of 72% and 82%, respectively.

The study also finds that:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK